Online citations, reference lists, and bibliographies.
← Back to Search

Topical Dexamethasone–cyclodextrin Nanoparticle Eye Drops For Non‐infectious Uveitic Macular Oedema And Vitritis – A Pilot Study

S. Shulman, G. Jóhannesson, E. Stefánsson, A. Loewenstein, A. Rosenblatt, Z. Habot-Wilner
Published 2015 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
To evaluate the safety and efficacy of 1.5% dexamethasone nanoparticle (DexNP) drops in eyes with non‐infectious uveitic macular oedema and vitritis.
This paper references
10.1016/j.ajo.2014.09.003
Multicenter study of intravitreal dexamethasone implant in noninfectious uveitis: indications, outcomes, and reinjection frequency.
J. Zarranz-Ventura (2014)
10.1016/j.ajo.2011.10.008
Efficacy and potential complications of difluprednate use for pediatric uveitis.
M. Slabaugh (2012)
10.1016/j.ophtha.2014.02.003
Treatment with repeat dexamethasone implants results in long-term disease control in eyes with noninfectious uveitis.
O. Tomkins-Netzer (2014)
10.1089/JOP.2006.125
Safety profile of intravitreal triamcinolone acetonide.
J. Baath (2007)
Randomized, double-blind, placebo-controlled clinical trial on the efficacy of 0.5% indomethacin
P Allegri (2014)
10.1167/iovs.13-13202
Randomized, double-blind, placebo-controlled clinical trial on the efficacy of 0.5% indomethacin eye drops in uveitic macular edema.
P. Allegri (2014)
10.1002/JPS.20047
Self-association of cyclodextrins and cyclodextrin complexes.
T. Loftsson (2004)
10.1167/iovs.11-8178
Topical dexamethasone-cyclodextrin microparticle eye drops for diabetic macular edema.
M. Tanito (2011)
10.1159/000078612
Uveitis: A Potentially Blinding Disease
O. Durrani (2004)
10.1016/J.AJO.2005.03.057
Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop.
D. Jabs (2005)
10.1007/s00417-013-2309-4
Bromfenac alone or with single intravitreal injection of bevacizumab or triamcinolone acetonide for treatment of uveitic macular edema
Alaa E. Radwan (2013)
10.2147/OPTH.S4684
Treatment of cystoid macular edema with the new-generation NSAID nepafenac 0.1%
S. Hariprasad (2009)
10.1691/PH.2008.7322
Topical drug delivery to the posterior segment of the eye: anatomical and physiological considerations.
T. Loftsson (2008)
10.1111/aos.12334
Kinetics of γ‐cyclodextrin nanoparticle suspension eye drops in tear fluid
G. Jóhannesson (2014)
Kinetics of c-cyclodextrin nanoparticle suspension eye
GM ımsd ottir (2014)
10.1016/J.OPHTHA.2006.03.027
Impact of macular edema on visual acuity in uveitis.
C. Lardenoye (2006)
Fluocinolone Acetonide Uveitis Study Group : fluocinolone acetonide implant ( Retisert ) for noninfectious posterior uveitis : thirty - four - week results of a multicenter randomized clinical study
GJ Jaffe (2006)
10.1002/jps.21861
Cyclodextrins as solubilizers: formation of complex aggregates.
P. Jansook (2010)
10.1136/bjo.80.9.844
The possible impact of uveitis in blindness: a literature survey.
M. S. Suttorp-Schulten (1996)
10.5301/EJO.2010.6062
Intravitreal Triamcinolone Acetonide as Adjunctive Treatment with Systemic Therapy for Uveitic Macular Edema
Z. Habot-Wilner (2011)
10.1001/archopht.126.9.1191
Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results.
D. Callanan (2008)
10.1001/archophthalmol.2011.82
Elevation of intraocular pressure in patients with uveitis treated with topical difluprednate.
Andrea D. Birnbaum (2011)
10.18433/J3M88B
yCD/HPyCD mixtures as solubilizer: solid-state characterization and sample dexamethasone eye drop suspension.
P. Jansook (2010)
Cyclodextrins and their Pharmaceutical Applications
Abdulrhman. A. Akasha (2014)
10.1016/J.IJPHARM.2007.04.029
Effect of the unstirred water layer on permeability enhancement by hydrophilic cyclodextrins.
M. Brewster (2007)
10.1016/j.ophtha.2014.05.021
Periocular corticosteroid injections in uveitis: effects and complications.
H. Sen (2014)
10.1111/J.1600-0420.2007.00885.X
Topical and systemic absorption in delivery of dexamethasone to the anterior and posterior segments of the eye.
H. Sigurdsson (2007)
10.1111/aos.12560
Topical dexamethasone–cyclodextrin microparticle eye drops for uveitic macular oedema
S. Krag (2014)
10.1016/J.AJO.2006.05.001
Reading performance of patients with uveitis-associated cystoid macular edema.
C. Kiss (2006)
10.1016/J.OPHTHA.2006.02.021
Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study.
G. Jaffe (2006)
10.1211/jpp.59.5.0002
Cyclodextrin microparticles for drug delivery to the posterior segment of the eye: aqueous dexamethasone eye drops
T. Loftsson (2007)



This paper is referenced by
10.1007/978-3-319-98080-5_3
Bioengineered and Regenerative Medicine Strategies for Retina Repair
Linyang Yu (2018)
10.1111/aos.14042
Suprachoroidally injected pharmacological agents for the treatment of chorio‐retinal diseases: a targeted approach
Z. Habot-Wilner (2019)
10.1007/s10847-019-00910-0
Preparation and characterization of diclofenac sodium β-cyclodextrin inclusion complex eye drops
S. Li (2019)
10.1111/aos.14119
Treatment of non‐infectious ophthalmic inflammatory diseases with 1.5% dexamethasone γ‐cyclodextrin nanoparticle eye drops
Katsue Imamachi (2019)
10.1111/aos.14370
Can postoperative dexamethasone nanoparticle eye drops replace mitomycin C in trabeculectomy?
G. Jóhannesson (2020)
10.1016/j.ijpharm.2017.04.010
Cyclodextrins and topical drug delivery to the anterior and posterior segments of the eye.
T. Loftsson (2017)
10.4155/tde-2017-0018
Approaches in topical ocular drug delivery and developments in the use of contact lenses as drug-delivery devices.
P. Mehta (2017)
10.1088/2515-7639/AAF263
Assessing the ex vivo permeation behaviour of functionalised contact lens coatings engineered using an electrohydrodynamic technique
P. Mehta (2018)
10.1016/j.drudis.2019.03.018
The gap between the need for novel retinal drug delivery methods, technologies in R&D phase, and approved ocular drug delivery technologies.
Ron Neumann (2019)
10.1111/bph.14024
Principles of pharmacology in the eye
S. Awwad (2017)
10.1097/ICU.0000000000000210
Local (topical and intraocular) therapy for ocular Adamantiades−Behçet's disease
Claudia Fabiani (2015)
10.1111/aos.13448
Preliminary study of a controllable device for subtenon drug infusion in a rabbit model
Yiqin Duan (2017)
10.1167/iovs.16-21377
An Ilomastat-CD Eye Drop Formulation to Treat Ocular Scarring
Abeer H. A. Mohamed-Ahmed (2017)
10.5772/INTECHOPEN.82388
A Novel Ocular Drug Delivery System of Dexamethasone Sodium Phosphate for Noninfectious Uveitis Treatment
K. Papangkorn (2018)
10.1111/ceo.13500
Viral retinitis: diagnosis and management in the era of biologic immunosuppression: A review
X. Wu (2019)
10.1016/J.JDDST.2018.04.007
Topical drug delivery to the posterior segment of the eye: Dexamethasone concentrations in various eye tissues after topical administration for up to 15 days to rabbits
S. Jóhannsdóttir (2018)
10.1007/s13346-016-0336-5
Pharmaceutical microscale and nanoscale approaches for efficient treatment of ocular diseases
I. Bravo-Osuna (2016)
10.1089/JOP.2017.0053
Noninvasive Ocular Drug Delivery System of Dexamethasone Sodium Phosphate in the Treatment of Experimental Uveitis Rabbit.
PapangkornKongnara (2017)
10.1016/j.biomaterials.2019.119285
Topical sustained drug delivery to the retina with a drug-eluting contact lens.
Amy E. Ross (2019)
10.1111/aos.13604
Intravitreal diclofenac for treatment of refractory uveitis‐associated cystoid macular oedema: A before and after clinical study
F. Kianersi (2018)
10.1111/aos.12955
Perioperative prophylaxis to prevent recurrence following cataract surgery in uveitic patients: a two‐centre, prospective, randomized trial
P. Mora (2016)
Semantic Scholar Logo Some data provided by SemanticScholar